Januvia Merck & Co., Inc. - Treatment for Type 2 Diabetes
Januvia is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.Posted: October 2006
Related Articles:
- Merck Announces FDA Acceptance of New Drug Application for Januvia, the Company's Investigational Medicine for Type 2 Diabetes - February 15, 2006
Januvia (sitagliptin phosphate) FDA Approval History
